The activities of the FOXO transcription factor and of the NFκB, JAK-STAT1/2, JAK-STAT3, Notch, and TGFβ signaling pathways were measured in resting and activated CD4+ T cells, in CD4+ T cells differentiated to Th1 and Th2 cells, in Treg cells, in CD4+ T cells incubated with breast cancer SN, and in a series of matched blood, lymph nodes, and TIL samples from patients with breast cancer. This evidence concerns the gene TGFB1 and breast carcinoma.